Skip to main content
OpenTrials
Completed

NCT Number: NCT02332642

Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy

This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immuno-monitoring

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie

Mannheim, 68167, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • histologically defined metastatic melanoma patients (AJCC stage IV)
  • aged 18 to 80 years
  • at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy

Exclusion criteria

  • therapy-naive patients
  • any contra-indications for (specific) systemic chemotherapy

Treatment and study plan

Immuno-monitoring

Other

Primary outcomes

  1. Immuno-monitoring

    Time frame: Immediate

Sponsors and collaborators

Lead sponsor

Universitätsmedizin Mannheim

Other

Registry information

Acronym: ImmunoPAX

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jan 7, 2015
Registry last updated
Mar 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.